Symphony vs IQVIA

Symphony and IQVIA are two leading healthcare companies that have been gaining attention in the stock market. Symphony specializes in providing technology solutions for the life sciences industry, while IQVIA offers a range of services for healthcare organizations and pharmaceutical companies. Both companies have shown strong growth potential in recent years, with Symphony focusing on innovative solutions and IQVIA on data analytics and research. Investors are closely watching these two stocks to see which one will outperform the other in the coming years.

Symphony or IQVIA?

When comparing Symphony and IQVIA, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Symphony and IQVIA.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Symphony has a dividend yield of 0.61%, while IQVIA has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Symphony reports a 5-year dividend growth of 0.00% year and a payout ratio of -10.14%. On the other hand, IQVIA reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Symphony P/E ratio at -16.62 and IQVIA's P/E ratio at 29.83. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Symphony P/B ratio is 1.00 while IQVIA's P/B ratio is 6.32.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Symphony has seen a 5-year revenue growth of -0.20%, while IQVIA's is 0.60%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Symphony's ROE at -5.91% and IQVIA's ROE at 22.79%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are HK$0.81 for Symphony and $231.84 for IQVIA. Over the past year, Symphony's prices ranged from HK$0.78 to HK$0.93, with a yearly change of 19.23%. IQVIA's prices fluctuated between $167.42 and $261.73, with a yearly change of 56.33%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.